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Abstract: The purpose of this study is to compare the neuro-
psychological profile of patients affected by parkinsonism
and vascular lesions to that in patients with PD alone (PD)
and to evaluate whether the brain vascular lesion load is
associated with neuropsychological variables. Thirty-six
nondemented patients with parkinsonism were divided into
3 groups of 12 patients each, according to both clinical his-
tory and the presence of brain vascular lesions and/or dopa-
minergic denervation as revealed by magnetic resonance
and dopamine transporter imaging, respectively. The first
group had vascular lesions without dopaminergic denerva-
tion (VP group); the second group had vascular lesions and
dopaminergic denervation (DD) (VP1DD group); and the
third group consisted of patients with dopaminergic dener-
vation (PD group) without vascular lesions. All patients
underwent neurological and neuropsychological assess-
ments. The groups differed in disease duration, age at onset,
and cerebrovascular risk factors. The VP and VP1DD
groups performed worse than the PD group on frontal/exec-
utive tasks. Regardless of the presence of dopaminergic de-
nervation, cerebrovascular lesions in hemispheric white mat-
ter, basal ganglia, and cerebellum have an important effect
in determining early onset and severity of cognitive impair-
ment in patients with parkinsonism. ! 2009 Movement
Disorder Society
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INTRODUCTION
In the absence of definite clinical diagnostic criteria,
vascular parkinsonism (VP) is defined as a Parkinson syn-
drome occurring in cerebrovascular disease, after exclu-
sion of Lewy body disease and other neurodegenerative
conditions.1–3 However, VP is difficult to distinguish
from Parkinson’s disease (PD), because basal ganglia
infarcts can occur without parkinsonism,4,5 and because a
vascular disorder may occur in Lewy-body PD.6
Magnetic resonance imaging (MRI) studies7,8 and a
clinicopathological correlation study2 suggested that
two types of vascular lesions might cause VP, i.e.,
widespread, bilateral ischemic lesions and basal gan-
glia infarcts.
Also clinically, VP can be difficult to distinguish
from PD, although recent studies have identified some
clinical aspects that differentiate between the two dis-
eases: primitive reflexes,9 preserved olfactory func-
tion,10 lower body parkinsonism,11 postural instability,
a history of stroke and risk factors for stroke, and fail-
ure to respond to levodopa (L-dopa) therapy.8,12,13
Previous studies reported that dementia2 or cognitive
impairment2,8,13 were significantly more common in
patients with VP than in patients with PD alone. In these
studies, cognitive processes were not assessed by means
of specific neuropsychological tasks, and the neuropsy-
chological profile of patients with VP has yet to be fully
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elucidated. The aim of our study was to evaluate the
relevance of vascular lesions in determining cognitive
impairment in patients with parkinsonism. To this aim,
both frontal lobe functions and memory were assessed
in three subpopulations of parkinsonian patients with:
(a) dopamine denervation without vascular lesions; (b)
vascular lesions without dopamine denervation; (c) both
vascular lesions and dopamine denervation.
PATIENTS AND METHODS
Patients
We evaluated 36 patients with parkinsonism without
dementia based on DSM IV criteria14 and an age- and
education-adjusted Mini-Mental State Examination
(MMSE) score ‡ 23.8.15,16 The diagnosis of parkinson-
ism was based on the presence of at least two of rest
tremor, rigidity, postural instability, and bradykinesia.
All patients underwent both brain MRI scan and [123I]
FP-CIT single-photon emission computed tomography
(SPECT) of dopamine transporter ([123I] FP-CIT-
SPECT). They were divided into three groups accord-
ing to clinical history and to the neuroimaging results.
The first group consisted of 12 patients with parkinson-
ism of insidious onset, lacunar lesions on MRI, and
normal [123I] FP-CIT-SPECT imaging; these subjects
were considered as a subset of patients with a diagno-
sis of vascular parkinsonism (VP group).3 The second
group consisted of 12 patients with parkinsonism of in-
sidious onset, lacunar lesions on MRI, and abnormal
[123I] FP-CIT-SPECT imaging; these subjects were
considered as a subset of patients affected by VP with
nigrostriatal dopaminergic denervation (DD) (VP1DD
group).3,17 The third group consisted of 12 patients
with probable idiopathic PD,18 without lacunar lesions
on MRI and with abnormal [123I] FP-CIT-SPECT
imaging (PD group).
MRI were obtained by 1.5T scanners. Axial (bicom-
missural plane), T2-weighted 5-mm thick fast-spin echo
(TE from 80 to 120 ms), and axial FLAIR 5-mm-thick
sections were rated by two experts, blinded to the
patient’s clinical condition. Vascular lesions in periven-
tricular regions, hemispheric white matter, basal gan-
glia/thalamus, and brainstem/cerebellum were evaluated
using the semiquantitative visual rating scale devised by
Scheltens et al. (0–84 points).19 The following items
were assessed: periventricular hyperintensities, the num-
ber, size and locations of lesions in hemispheric white
matter (frontal, parietal, occipital, and temporal lobes),
basal ganglia (caudate, putamen and globus pallidus,
thalamus, and internal capsule), and infratentorial foci
(cerebellum, midbrain, pons, and medulla).
Dopamine transporter imaging was obtained by
means of [123I] FP-CIT SPECT. All images were visu-
ally evaluated by an experienced nuclear medicine doc-
tor blind to patients’ clinical condition and classified
into normal and abnormal (unilateral, mild-to-moderate
bilateral, severe bilateral) according to the current
literature.20
Procedure
The assessment was performed in the morning, in a
single session that lasted approximately 3 hours, with a
break to avoid fatigue. Clinical, neuropsychiatric, and
neuropsychological features were evaluated in all
patients under medication. If the patients had motor
fluctuations, all evaluations were made during the
motor ON-phase before being tested; all patients gave
their written informed consent to participate in the
study.
Neurological Assessment
All patients with PD underwent a neurological ex-
amination by means of motor section of the Unified
Parkinsons’ Disease Rating Scale (UPDRS-section
III)21 and the Hoehn and Yahr scale22 to measure se-
verity of motor symptoms in ‘‘on’’ state. Furthermore,
we recorded demographic details (age and educational
level), neurological details, namely disease duration,
age at PD onset, and type of onset (acute vs. subacute
vs. insidious; symmetric vs. asymmetric), cerebrovas-
cular risk factors, namely familiarity, hypertension
(blood pressure > 140 mm Hg systolic and > 90 mm
Hg diastolic), diabetes mellitus (fasting blood glucose
level > 130 mg/dL), smoking (at least 20 cigarettes
per day), hyperlipidemia (total cholesterol > 5.7
mmol/L), heart disease (coronary heart disease and car-
diomyopathy), and hypotension (blood pressure < 90
mm Hg systolic and < 60 mm Hg diastolic). Total L-
dopa equivalent daily dose (calculated as the sum of
the L-dopa and DA agonists converted into L-dopa
equivalent daily dose, LEDD) and chronic response to
L-dopa (considered as sustained clinical improvement
using at least 500 mg/day for at least 3 months) were
recorded.
Neuropsychiatric Assessment
All patients underwent neuropsychiatric examination
with: (1) the Hamilton Depression Rating Scale (Ham-
D)23,24 to measure the severity of depressive symp-
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toms; and (2) the Neuropsychiatric Inventory (NPI)25
to identify neuropsychiatric disturbances.
Neuropsychological Assessment
All 36 patients underwent standardized neuropsycho-
logical tasks to assess frontal lobe/executive functions
and memory.
Frontal Lobe/Executive Functions
To evaluate frontal lobe functions, we used the
Frontal Assessment Battery (FAB) screening instru-
ment.26 Specific frontal lobe functions were assessed
as follows: (1) cognitive flexibility by means of the
Phonological27 and Semantic28 verbal fluency tasks
and the Wisconsin Card Sorting Test (WCST)29,30; (2)
logical abstract thinking by means of Raven’s Colored
Progressive Matrices (RCPM)27; (3) spatial planning
by means of copying task included in the Rey-Oster-
rieth Complex Figure Test (ROCF)31 and the Clock
Drawing Test (CDT)32; (4) set-shifting by means of
the Trail Making Test (TMT),33 a task consisting of
two parts: part A (TMT-A) measures motor speed and
visual research, and part B (TMT-B) provides a mea-
sure of frontal lobe functions. We considered the dif-
ference in score between TMT-A and TMT-B
(TMT:B-A), a measure of set shifting; and (5) selective
attention by means of Attentional Matrices, a cancella-
tion task in which subjects are required to mark desig-
nated target number(s) within a 6 3 10 matrix filled
with digits. Score range: 0 to 60.28
Memory
To evaluate the verbal long-term memory, we used
the Rey auditory 15-word learning test27 including im-
mediate and delayed recall of word lists.
Statistical Analysis
Differences in the distribution of categorical varia-
bles among groups were assessed by means of v2 test.
Group comparisons on demographic and clinical con-
tinuous variables were performed by means of analysis
of variance (ANOVA). For the analysis of differences
among groups on neuroradiological, neuropsychiatric,
and neuropsychological variables, we adopted distribu-
tion-free nonparametric tests (Mann-Whitney U-test for
comparing two samples, Kruskal-Wallis test for com-
paring three samples) to avoid biases due to the rela-
tively small sample size. Moreover, to avoid type-I
errors, we adopted a conservative statistical approach
and applied Bonferroni’s correction for the significance
level (P5 0.004 for the neuropsychological tests; P5
0.025 for the neuropsychiatric data). The association
between variables was assessed by the nonparametric
Spearman correlation coefficient.
RESULTS
Clinical Results
Demographic and clinical findings are reported in
Table 1. ANOVA showed no significant differences
among the 3 groups of patients with respect to age,
educational level, or severity of motor symptoms
(UPDRS-section III and the Hoehn and Yahr scale).
Patients of the PD group had a longer disease duration
and a lower age at onset than patients with VP and
patients with VP1DD. The type (symmetric vs. asym-
metric and acute vs. subacute vs. insidious) of disease
onset in patients of 3 groups was reported in Table 1.
The prevalence of several cerebrovascular risk factors
(heart disease, diabetes mellitus, hyperlipidemia, hyper-
tension, and familiarity for vascular disease) signifi-
cantly differed among the 3 groups (see Table 1).
With respect to antiparkinsonian treatment, the L-
dopa equivalent daily dose did not differ among the 3
groups, but the response to chronic L-dopa did (Table
1). Neuroimaging results are reported in Table 2. With
respect to vascular load, PD group had no lesion by
definition; VP group presented more hyperintensities
than VP1DD group in all studied brain regions,
though differences between VP and VP1DD groups
did not reach statistical significance (hemispheric white
matter, P 5 0.244; basal ganglia, P 5 0.800; infraten-
torial foci, P 5 0.366). Dopamine transport imaging
identified both PD and VP1DD groups as having
abnormal [123I] FP-CIT SPECT. VP group was identi-
fied by normal [123I] FP-CIT SPECT.
Neuropsychiatric and Neuropsychological Results
The behavioral and cognitive data of the 3 groups of
patients are reported in Table 3. The results showed
that Ham-D and NPI scores did not significantly differ
among the 3 groups of patients.
Regarding neuropsychological scores, 4 patients (3
patients from the VP group and 1 patient from the
VP1DD group) were excluded from the analysis
because of missing data: 3 patients did not perform the
TMT-B because of difficulty in recalling letters of the
alphabet (due to low education level), while 1 did not
perform the ROCF because of severe tremor. As shown
in Table 3, significant differences among 3 groups
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were observed on the FAB and on semantic fluency
task, whereas differences for phonological fluency task,
RCPM, Attentive Matrices, and TMT-A did not reach
the Bonferroni-corrected significance level. No signifi-
cant difference among 3 groups of patients occurred on
the remaining cognitive tasks. The Mann-Whitney U-
test for comparing two samples showed that VP1DD
patients performed worse than patients of the PD group
on FAB, RCPM and Attentive Matrices, TMT-A,
semantic fluency tasks. Moreover, patients with VP
had significantly lower score than patients with PD on
phonological and semantic fluency tasks and TMT-A.
Further analysis did not show significant correlations
between brain MRI load and neuropsychiatric or neu-
ropsychological scores. Similarly, brain MRI load was
unrelated to clinical data.
DISCUSSION
In this study, we compared the neuropsychological
profile of patients affected by VP, PD, and VP1DD.
Although patients with PD had an earlier onset and
longer disease duration than patients with both VP and
VP1DD, patients with vascular abnormalities (with or
without concomitant dopaminergic denervation) had
more severe frontal lobe dysfunctions as assessed by
means of verbal fluency tasks than patients with PD
alone. Furthermore, impairment of frontal lobe func-
tions including cognitive flexibility, selective attention,
and logical abstract thinking was more severe in
patients with VP1DD than with PD.
Taken together, our neuropsychological findings
indicate that vascular lesions are related to severe fron-
tal lobe dysfunctions in patients with VP and patients
with VP1DD, which is in line with previous neuro-
pathological and neuroimaging studies.7,8,34,35 There-
fore, our data suggest that vascular lacunar infarcts in
the deep white matter of the frontal lobe, caudate, or
putamen may cause dysfunction of frontostriatal cir-
cuits and thus induce severe executive/frontal lobe dys-
functions. Although previous reports36 in PD did not
find significant relationships between cognitive altera-
TABLE 1. Demographic and clinical aspects of patients in the PD, VP, and VP1DD groups
PD group (n 5 12) VP group (n 5 12) VP1DD group (n 5 12) F P
Characteristics
Men/Women 11/1 9/3 8/4 2.250 0.325
Age (yr) 68.7 6 6.9 72.2 6 4.5 71.2 6 4.9 1.303 0.285
Education (yr) 9.8 6 4.2 7.3 6 4.5 6.1 6 3.4 2.629 0.087
Age at PD onset (yr) 57.8 6 10.7 68.2 6 5.6a 67.4 6 4.6a 7.159 0.003
Acute/subacute/insidious onset 2/6/4 0/2/10 0/0/12 – –
Symmetric/asymmetric onset 0/12 6/6 2/10 – –
PD duration (yr) 10.7 6 5.3 4 6 2.8a 3.5 6 1.2a 15.252 0.001
LEDD (mg/day) 680.2 6 269.5 454.6 6 290.5 462.5 6 257.7 2.641 0.086
Hoehn and Yahr score 1.9 6 0.6 2.3 6 1.2 1.9 6 0.6 0.560 0.577
UPDRS-III score in ‘‘on’’ state 16.7 6 6.9 21.7 6 9.1 24 6 8.2 2.492 0.098
MMSE 27.8 6 1.5 25.6 6 3.6 25.5 6 3.2 2.352 0.111
Response to chronic levodopa (no/yes) 0/12 12/0 2/10 – –
Cerebrovascular risk factors Chi-square P
Hypertension (no/yes) 9/3 1/11 1/11 16.756 <0.001
Familiarity for vascular disease (no/yes) 12/0 3/9 2/10 20.285 <0.001
Hyperlipidemia (no/yes) 12/0 4/8 4/8 14.400 0.001
Heart disease (no/yes) 11/1 4/8 4/8 10.923 0.004
Smoking (no/yes) 11/1 9/3 8/4 2.250 0.325
Diabetes mellitus (no/yes) 12/0 7/5 9/3 6.107 0.047
Hypotension (no/yes) 12/0 12/0 12/0 – –
Group comparisons on demographic and clinical continuous variables were performed by means of analysis of variance (ANOVA).
aSignificantly different from the PD group on Bonferroni posthoc tests.
LEDD, levodopa dose equivalent; UPDRS-III score, Unified Parkinson’s Disease Rating Scale; MMSE, Mini-Mental State Examination.
TABLE 2. Neuroimaging results in patients in the PD, VP, and VP1DD groups
PD group (n 5 12) VP group (n 5 12) VP1DD group (n 5 12)
Vascular load Hemispheric white matter hyperintensities 0 11.7 6 8.4 7.7 6 6.6
Basal ganglia/thalamus hyperintensities 0 6.7 6 5.7 5.9 6 8.2
Infratentorial foci of hyperintensities 0 1.4 6 1.9 0.8 6 0.8
DATSCAN Subjects: normal/abnormal 0/12 12/0 0/12
The values of vascular load represented as mean 6 standard deviation of semiquantitave visual rating scale.19
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tions and mild-to-moderate cerebrovascular lesions in
PD, Jellinger36 observed a significant increase of cog-
nitive dysfunctions in patients with PD with severe
cerebrovascular lesions pathologically proven. Simi-
larly, we found more severe cognitive impairment in
patients with cerebrovascular lesions (regardless of the
presence of dopaminergic denervation) than in patients
with PD alone. These data may indicate that extensive
cerebrovascular lesions may have an important effect
in determining severity and extent of cognitive dys-
functions as suggested previously.36
We found no significant correlations between vascu-
lar lesion load and cognitive scores. On the other hand,
in 170 patients with mild cognitive impairment (MCI),
a significant correlation was found between subcortical
and periventricular white matter hyperintensities and
executive dysfunctions.37 This inconsistency might
reflect either the different study population (PD vs.
MCI) or the small sample size of our study. It is possi-
ble that the evaluation of interhemispheric differences
might have revealed correlations between cognitive
dysfunctions and vascular lesions. Unfortunately, the
visual rating scale19 used in our study does not evalu-
ate such interhemispheric differences. Another limita-
tion of this study is the lack of cortical damage and/or
cortical atrophy evaluation.
In accordance with previous studies, we found that
patients with VP and patients with VP1DD had more
severe vascular risk factors (hypertension, familiarity
for vascular disease, hyperlipidemia, heart disease, and
diabetes mellitus),1,8,12,13,34,38 an older age at onset,
and a shorter duration of disease than patients with PD
alone.8,12,13,34,35,39,40 These data lend weight to Critch-
ley’s suggestion that a later onset age would favor a
vascular cause.1
In line with earlier reports,1,7,8,12,13,34,35,38,40,41 our
patients with VP did not respond to treatment with L-
dopa, whereas patients with PD alone did. Therefore,
our results support the concept proposed by Zijlmans
et al.42 that a negative response to L-dopa in VP is
related to the absence of macroscopic lesions in the ba-
sal ganglia and that VP might be associated with wide-
spread frontal white matter lesions, relatively slight ba-
sal ganglia lesions, and good preservation of pigmented
neurons in the substantia nigra. Moreover, 10 of 12
patients in our VP1DD group (83.3%) responded to L-
dopa treatment, which indirectly supports the idea that
a good response to L-dopa may be related to the pres-
TABLE 3. Behavioral and cognitive comparisons among the PD, VP, and VP1DD groups
PD group (n 5 12) VP group (n 5 12) VP1DD group (n 5 12) P
Neuropsychiatric parameters
HAM-D 11.6 6 6.9 12 6 7.3 10.4 6 6.7 0.397
NPI-12 14.2 6 12.7 15.8 6 14.1 15.7 6 14.9 0.994
Neuropsychological parameters PD group (n 5 12) VP group (n 5 9) VP1DD group (n 5 11) P
Frontal functions
FAB 14.3 6 2.3 12.7 6 2.8 10.8 62.3a 0.003
Cognitive flexibility
WCST-global score 48.2 6 14.4 43.1 6 18.1 43.1 6 10.4 0.541
Phonological fluency 31.3 6 10.8 19.9 6 9.7 18.4 6 8.6 0.005
Semantic fluency 16.5 6 3.9 11.4 6 3.4a 10.3 6 4.1a 0.002
Logical abstract thinking
RCPM 25.8 6 4.3 24.2 6 6.1 20.2 6 4.1 0.023
Spatial planning
ROCF-copy task 26.8 6 5.9 25 6 8.2 25.7 6 7.5 0.690
CDT 6.8 6 3 6.8 6 3.7 5.4 6 3.7 0.566
Set-shifting
TMT-A 58.4 6 27.8 93.6 6 28.1 104.3 6 66.9 0.011
TMT-B 181.9 6 98.7 328.2 6 204.5 322.6 6 190.7 0.069
TMT: B-A 123.5 6 97.6 234.7 6 189.1 218.4 6 139.1 0.183
Selective attention
Attentive matrices 44.7 6 13.7 43.8 6 5.8 37.5 6 7.8 0.043
Memory
Immediate recall 42.2 6 10.4 32.9 6 6.4 35.4 6 9.1 0.063
Delayed recall 8.6 6 2.8 7.6 6 2.8 7 6 2.6 0.252
Group comparisons on neuropsychiatric and neuropsychological variables were performed by means of nonparametric tests (Kruskal-Wallis test
for comparing the three samples). In case of statistically significant differences among the three groups (threshold for significance level was calcu-
lated P < 0.004 after Bonferroni correction), posthoc tests were performed by means of Mann-Whitney U-test for comparing two samples.
aSignificantly different from PD.
HAM-D, Hamilton Depression Rating Scale; NPI, Neuropsychiatric Inventory; FAB, Frontal Assessment Battery; WCST, Wisconsin Card Sort-
ing Test; RCPM, Raven’s Colored Progressive Matrices; ROCF, Rey-Osterrieth Complex Figure Test; CDT, Clock Drawing Test; TMT, Trail
Making Test.
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ence of vascular and/or degenerative lesions predomi-
nating in or near the nigrostriatal pathway.42
Taken together, our findings suggest that cerebrovas-
cular lesions especially in patients with PD may have
an important effect in determining early onset and
severe impairment of cognitive functions, mainly of
frontal lobe functions. Therefore, in the clinical setting,
besides assessing neurological status, the neurologist
should also evaluate cognitive functions by means of a
comprehensive neuropsychological examination in
patients presenting suspected VP with and without de-
generative PD.
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